An Phase III Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With PsO
Clinical trial NCT06299982 · UNKNOWN
Trial details
- NCT number
- NCT06299982
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-05-15
- Primary completion
- 2025-01-30
- Enrollment
- 750
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.